Abstract
Introduction: Tumor necrosis factor-α (TNF-α)-blocking agents are drugs approved for the treatment of inflammatory bowel diseases (IBDs). Infliximab and adalimumab are approved for the treatment of IBD in the pediatric setting with the improvement of therapeutic management. Biological agents, also in the pediatric population, can be administered either alone or in combination with immunomodulators. Their use has raised safety concerns regarding the risk of infections and malignancies. Areas covered: A broad review of the safety concerns for the use of anti-TNF-α drugs in children with IBD was performed, and information regarding the risk of infections and malignancies were updated, also in comparison with the safety of traditional drugs such as steroids and/or immunosuppressants. Expert commentary: Anti-TNF-α drugs have shown favorable safety profiles, and adalimumab treatment is associated with lower immunogenicity compared with infliximab. Heightened awareness and vigilant surveillance leading to prompt diagnosis and treatment are important for optimal management.
| Original language | English |
|---|---|
| Pages (from-to) | 1-5 |
| Number of pages | 5 |
| Journal | Expert Review of Gastroenterology and Hepatology |
| DOIs | |
| Publication status | E-pub ahead of print - Sep 6 2019 |
Fingerprint
Cite this
Infections and malignancies risks related to TNF-α-blocking agents in pediatric inflammatory bowel diseases. / Alvisi, Patrizia; Dipasquale, Valeria; Barabino, Arrigo; Martellossi, Stefano; Miele, Erasmo; Lionetti, Paolo; Lombardi, Giuliano; Cucchiara, Salvatore; Torre, Giuliano; Romano, Claudio.
In: Expert Review of Gastroenterology and Hepatology, 06.09.2019, p. 1-5.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Infections and malignancies risks related to TNF-α-blocking agents in pediatric inflammatory bowel diseases
AU - Alvisi, Patrizia
AU - Dipasquale, Valeria
AU - Barabino, Arrigo
AU - Martellossi, Stefano
AU - Miele, Erasmo
AU - Lionetti, Paolo
AU - Lombardi, Giuliano
AU - Cucchiara, Salvatore
AU - Torre, Giuliano
AU - Romano, Claudio
PY - 2019/9/6
Y1 - 2019/9/6
N2 - Introduction: Tumor necrosis factor-α (TNF-α)-blocking agents are drugs approved for the treatment of inflammatory bowel diseases (IBDs). Infliximab and adalimumab are approved for the treatment of IBD in the pediatric setting with the improvement of therapeutic management. Biological agents, also in the pediatric population, can be administered either alone or in combination with immunomodulators. Their use has raised safety concerns regarding the risk of infections and malignancies. Areas covered: A broad review of the safety concerns for the use of anti-TNF-α drugs in children with IBD was performed, and information regarding the risk of infections and malignancies were updated, also in comparison with the safety of traditional drugs such as steroids and/or immunosuppressants. Expert commentary: Anti-TNF-α drugs have shown favorable safety profiles, and adalimumab treatment is associated with lower immunogenicity compared with infliximab. Heightened awareness and vigilant surveillance leading to prompt diagnosis and treatment are important for optimal management.
AB - Introduction: Tumor necrosis factor-α (TNF-α)-blocking agents are drugs approved for the treatment of inflammatory bowel diseases (IBDs). Infliximab and adalimumab are approved for the treatment of IBD in the pediatric setting with the improvement of therapeutic management. Biological agents, also in the pediatric population, can be administered either alone or in combination with immunomodulators. Their use has raised safety concerns regarding the risk of infections and malignancies. Areas covered: A broad review of the safety concerns for the use of anti-TNF-α drugs in children with IBD was performed, and information regarding the risk of infections and malignancies were updated, also in comparison with the safety of traditional drugs such as steroids and/or immunosuppressants. Expert commentary: Anti-TNF-α drugs have shown favorable safety profiles, and adalimumab treatment is associated with lower immunogenicity compared with infliximab. Heightened awareness and vigilant surveillance leading to prompt diagnosis and treatment are important for optimal management.
U2 - 10.1080/17474124.2019.1663173
DO - 10.1080/17474124.2019.1663173
M3 - Article
C2 - 31490707
SP - 1
EP - 5
JO - Expert Review of Gastroenterology and Hepatology
JF - Expert Review of Gastroenterology and Hepatology
SN - 1747-4124
ER -